EGFR and non-small cell lung carcinoma: The phase 3 ORIENT-31 research recruited 444 locally advanced or metastatic NSCLC patients with EGFR-mutant who progressed after previous EGFR-TKI treatment and categorized them into sintilimab + IBI305 (a biosimilar of bevacizumab) + pemetrexed + cisplatin group, sintilimab + pemetrexed + cisplatin group, and chemotherapy alone group.